A drug widely available in Europe and Canada – but not the United States – dramatically eases one of the most disabling symptoms of Huntington’s disease, involuntary writhing movements known as chorea ...

This is a follow up article to my call in November 2014 to ' Buy Auspex Ahead of Phase 3 Data ' in December. On December 16, 2014, Auspex Pharmaceuticals, Inc. (NASDAQ: ASPX) announced positive ...

Huntington's chorea (also known as St. Vitus' dance) is a rare brain disorder that causes, among other symptoms, uncontrollable, jerky movements in individuals. Photo: Getty Images/Science Photo ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington’s disease, according to a recent international study led by UTHealth Houston researcher Erin Furr ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...

Chorea Huntington (known as "Veitstanz" in German) is a rare brain disorder that causes uncontrollable, jerky movements in individuals. Photo: Getty Images/Science Photo Library RF Huntington’s ...

Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...

A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...

Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use ...

The US Food and Drug Administration (FDA) has approved deutetrabenazine extended-release tablets (Austedo XR, Teva), a new once-daily formulation of the drug for adults with tardive dyskinesia (TD) or ...